Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EBOS Group Limited ( (AU:EBO) ) has issued an announcement.
EBOS Group Limited has reported that 6,465 performance rights have lapsed, leaving 1,444,595 performance rights currently on issue. The adjustment marginally reduces the potential future dilution from equity-based incentives and provides investors with an updated picture of the company’s outstanding performance rights, clarifying the scale of its long-term incentive arrangements for key personnel.
The most recent analyst rating on (AU:EBO) stock is a Hold with a A$26.00 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the AU:EBO Stock Forecast page.
More about EBOS Group Limited
EBOS Group Limited is a trans-Tasman healthcare and pharmaceutical products distributor and marketer, serving pharmacies, hospitals, medical professionals and other healthcare providers in New Zealand and Australia.
Average Trading Volume: 131,055
Technical Sentiment Signal: Sell
Current Market Cap: A$4.55B
For an in-depth examination of EBO stock, go to TipRanks’ Overview page.